XTRA:BAYNPharmaceuticals
Assessing Bayer (XTRA:BAYN) Valuation After Heavy Annual Losses And A Strong 1‑Year Return
Bayer (XTRA:BAYN) has recently drawn investor attention after reporting annual revenue of €45.575b alongside a net loss of €3.620b. This has prompted fresh questions about how its three core segments support the current share price.
See our latest analysis for Bayer.
Despite the latest results, Bayer’s recent 1-day share price return of a 3.85% decline and 7-day share price return of a 6.33% decline suggest near-term sentiment has cooled, while the 1-year total shareholder return of 68.27%...